• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21804 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     Andalusian Health Technology Assessment Area (AETSA) Intra-abdominal vagal nerve blockade and malabsortive devices for severe obesity.
2017     Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with HPV vaccination
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema]
2017     NIHR Health Technology Assessment programme Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial
2017     NIHR Health Services and Delivery Research programme The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy
2017     NIHR Health Services and Delivery Research programme Seclusion and Psychiatric Intensive Care Evaluation Study (SPICES): combined qualitative and quantitative approaches to the uses and outcomes of coercive practices in mental health services
2017     Andalusian Health Technology Assessment Area (AETSA) Hip arthroplasty in patients with osteoarthritis
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Addendum to commission A16-74]
2017     NIHR Health Technology Assessment programme Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2017     NIHR Health Services and Delivery Research programme Elective hospital admissions: secondary data analysis and modelling with an emphasis on policies to moderate growth
2017     NIHR Health Services and Delivery Research programme Decommissioning health care: identifying best practice through primary and secondary research a prospective mixed-methods study
2017     Andalusian Health Technology Assessment Area (AETSA) Direct acting antivirals for the chronic hepatitis C infection. Relative assessment of efficacy and safety. Executive summary
2017     Adelaide Health Technology Assessment (AHTA) Prosigna (PAM50) for predicting breast cancer recurrence
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Services and Delivery Research programme Critical time Intervention for Severely mentally ill Prisoners (CrISP): a randomised controlled trial
2017     NIHR Health Services and Delivery Research programme Evaluating the effectiveness and cost-effectiveness of British Sign Language Improving Access to Psychological Therapies: an exploratory study
2017     Penn Medicine Center for Evidence-based Practice (CEP) Epidemiology of spectator injuries at baseball games
2017     Andalusian Health Technology Assessment Area (AETSA) Multitarget stool DNA testing for colorectal cancer screening.
2017     Adelaide Health Technology Assessment (AHTA) Processing and cryopreservation of semen, sperm and testicular tissue prior to or after gonadotoxic treatment to preserve future fertility
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - Addendum to commission H16-02B]
2017     NIHR Health Services and Delivery Research programme An evaluation of the effectiveness of annual health checks and quality of health care for adults with intellectual disability: an observational study using a primary care database
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement (TAVI) in Austria. Part 2: Data analysis]
2017     Adelaide Health Technology Assessment (AHTA) Magnetic Resonance Imaging of patients with suspected non-ischaemic cardiomyopathies
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and intrahepatic bile ducts - Addendum to commission H16-02D]
2017     Technology Assessment Unit of the McGill University Health Centre (MUHC) Plerixafor as first-line choice for stem cell mobilization in non-Hodgkin's lymphoma and multiple myeloma patients
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Social return on investment: outcomes, methods, and economic parameters
2017     Adelaide Health Technology Assessment (AHTA) Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systemic therapy in adults as a psychotherapeutic approach]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy
2017     Adelaide Health Technology Assessment (AHTA) Assessment of extended half-life clotting factor concentrates
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Perinatal care at the threshold of viability; Part I: Systematic analysis of outcomes and resource needs for neonatal intensive care units to inform healthcare planning
2017     Adelaide Health Technology Assessment (AHTA) Substitution of 68-Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Robotic surgery]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reslizumab (asthma) - Addendum to Commission A17-02]
2017     Agency for Healthcare Research and Quality (AHRQ) The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Definition of the stages of labour]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
2017     NIHR Health Technology Assessment programme The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2017     NIHR Health Services and Delivery Research programme Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Psychotherapy - concepts, effect factors and a comparison of legal regulations in three German speaking countries]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tenofovir alafenamide (chronic hepatitis B) - Benefit assessment according to §35a Social Code Book V]
2017     Agency for Healthcare Research and Quality (AHRQ) Treatment for adults with schizophrenia
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of issuing longer versus shorter duration (3-month vs. 28-day) prescriptions in patients with chronic conditions: systematic review and economic modelling
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06]
2017     NIHR Public Health Research (PHR) programme The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2017     Agency for Healthcare Research and Quality (AHRQ) Treatments for basal cell and squamous cell carcinoma of the skin
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer
2017     Technology Assessment Unit of the McGill University Health Centre (MUHC) Use of extracorporeal membrane oxygenation for cardiac life support in adult subjects
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy
2017     Belgian Health Care Knowledge Centre (KCE) Static automated external defibrillators for opportunistic use by bystanders
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis) - Addendum to Commission A17-08]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the LEADER study on liraglutide - rapid report]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14]
2017     HAYES, Inc. Antibiotic-impregnated bone cement for knee arthroplasty
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2017     HAYES, Inc. Capsule endoscopy for the diagnosis of small bowel Crohn's disease
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Core Outcome Data set for Dementia clinical trials (COD Dementia)
2017     HAYES, Inc. Coronary artery calcium scoring for risk assessment and stratification of coronary artery disease in asymptomatic adults
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2017     HAYES, Inc. Flow diverter devices for intracranial aneurysms: a review of reviews
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2017     HAYES, Inc. High-Intensity focused ultrasound for salvage therapy of recurrent prostate cancer
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Addendum to commission A17-11]
2017     HAYES, Inc. Hydrogen breath tests for diagnosis of small intestinal bacterial overgrowth in functional bowel disorders
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2017     HAYES, Inc. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD)
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - Addendum to commission H16-02C]
2017     HAYES, Inc. Percutaneous kyphoplasty for osteoporotic vertebral compression fractures
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)]
2017     NIHR Health Technology Assessment programme Facet joint injections for people with persistent non-specific low back pain (Facet Injection Study): a feasibility study for a randomised controlled trial
2017     HAYES, Inc. Proton beam therapy for non-small cell lung cancer
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2017     NIHR Health Technology Assessment programme A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial)
2017     HAYES, Inc. Radiofrequency ablation for sacroiliac joint denervation for chronic low back pain
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2017     HAYES, Inc. Collagen meniscus implant (CMI) (Menaflex; Ivy Sports Medicine LLC) for meniscal repair
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2017     HAYES, Inc. Continuous subcutaneous treprostinil for treatment of pulmonary arterial hypertension
2017     Health Quality Ontario (HQO) Fibreglass total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neuropathic foot ulcers: a health technology assessment
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]